Drugs in development · updated 9 November 2026
Iloprost: clinical trials and development status
Other names and codes: Ilomedin, Aurlumyn, Ventavis
As of 9 November 2026 Iloprost is in 3 active clinical trials (recruiting or ongoing, phases I–III) for 4 diseases. The most advanced phase is III.
Summary updated every week · data as of 9 November 2026. In Phuturdex you can follow Iloprost and get an email at every change or safety alert.
Sign in free →Approved uses in the United States (FDA)
AURLUMYN is a prostacyclin mimetic indicated for the treatment of severe frostbite in adults to reduce the risk of digit amputations. Effectiveness was established in young, healthy adults who suffered frostbite at high altitudes. […]
Source: FDA label of Aurlumyn, section «Indications and Usage» (openFDA), version of 13 August 2026
Official documents
Use, doses, side effects and interactions: only these official documents are authoritative.
Diseases studied
For each disease: the drug’s most advanced phase and active trials, with the reference trial on ClinicalTrials.gov.
| Disease | Most advanced phase | Active trials | Reference trial |
|---|---|---|---|
| Sickle-cell disease | III | 1 | NCT07498309 |
| Vaso-occlusive crisis | III | 1 | NCT07498309 |
| Fractures, Bone | II | 1 | NCT07924722 |
| Fractures, Ununited | II | 1 | NCT07924722 |
Everything on Iloprost
In Phuturdex you get every trial with sponsors, countries and dates, development events, FDA and EMA approvals, patents and exclusivities, orphan designations and safety alerts, with PDF and Excel export. Free until 31 March 2027.
Open in Phuturdex →Source: Phuturdex analysis of ClinicalTrials.gov (U.S. National Library of Medicine), FDA and EMA data, updated 9 November 2026. Active trials = recruiting or ongoing, phases I–III. Diseases are those named by each trial (NLM MeSH terms). The estimated launch, when shown, is a Phuturdex calculation described on the Method page, not official data.